Combining Automated Liquid Handling, Cellular Microscopy and Magnetic Bioprinting to Create Walk Away 3D Oncology, Stem Cell Differentiation, and Toxicity Procedures
The use of cells cultured into a three-dimensional (3D) configuration continues to gain acceptance within multiple areas of life science research and drug discovery. Assay procedures commonly performed with two-dimensional (2D) cultured cells are rapidly migrating to 3D because of the reestablishment of cell-cell and cell-extracellular matrix (ECM) interactions, and in vivo-like results these cell models afford. Examples include cell migration studies, stem cell differentiation, and toxicity assessments. Magnetic bioprinting is a versatile method for aggregating cells and fomenting ECM interactions that can be used across multiple assay procedures. Using this technology, cells can be printed into 3D ring, dot, or spheroid structures after biocompatible magnetic particles are attached.
In this webinar we will demonstrate how assay procedures using 3D magnetic bioprinting can be performed in a walk-away manner using automated liquid handling and incubation, and monitored through fluorescent and label-free image-based analysis.
Watch this webinar
© BioTek Instruments, Inc. All Rights Reserved.
Jan Seldin - Greiner Bio-One, Monroe, NC
Jan Seldin obtained her Bachelor of Science at Frostburg State College in Maryland, where she studied Chemistry and Mathematics. Prior to joining Greiner Bio-One in 2001, her scientific career involved work within Clinical Chemistry, Biochemistry, Immunology, Pharmacology and Pre-Clinical Drug Development laboratories in Medical, Academic and Pharmaceutical organizations.
As Senior Product Manager of Microplates, Separations, Cryopreservation and Biobanking, Jan acts as an inter-departmental corporate liaison, responsible for market intelligence, logistics, product sales support and training. Jan may be reached by email at email@example.com.
Glauco Souza - n3D Biosciences, Inc., Houston, TX
Glauco R. Souza is President, CSO, and co-founder of Nano3D Biosciences (n3D). n3D was founded in 2008. Before n3D, Dr. Souza received his Ph.D. in Chemistry from the George Washington University, and was a postdoctoral associate at MD Anderson Cancer Center, where he conceptualized magnetic 3D bioprinting. He currently holds a cross appointment with University of Texas Health Science Center Houston, TX as Adjunct Assistant Professor.
Brad Larson - BioTek Instruments, Inc., Winooski, VT
Brad Larson is a Principal Scientist at BioTek Instruments, Inc. His roles include optimizing new drug discovery assay chemistries and cell culture models on BioTek’s line of automation, microplate detection, and imaging instrumentation. He has worked for more than 15 years with numerous automation and detection platforms to optimize a variety of assays in the drug discovery field, including kinase, GPCR, epigenetics, drug metabolism, toxicity, and antibody therapeutic assays.